Worries and Concerns among Inflammatory Bowel Disease Patients Followed Prospectively over One Year
Table 3
Determination of the RFIPC’s ability to discriminate between IBD symptom severity scores at baseline.
UC (n = 92)
None
Mild
Moderate/severe
F-value
P-value
RFIPC dimensions
F1 Impact of disease
15.5 (12.6)
29.1 (20.0)
43.2 (18.8)
14.895
<0.001
F2 Expectancy
23.5 (17.1)
40.6 (26.0)
44.6 (24.9)
5.584
0.005
F3 Treatment
15.7 (11.2)
34.5 (23.1)
42.6 (25.7)
10.082
<0.001
F4 Intimacy
9.4 (9.6)
21.4 (17.4)
28.1 (24.4)
6.723
0.002
F5 Stigma
11.0 (13.0)
21.1 (22.1)
29.6 (22.7)
5.205
0.007
F6 Complications
15.8 (15.1)
30.2 (15.6)
38.0 (17.8)
4.142
0.019
Sum score
16.0 (11.3)
30.2 (15.6)
38.0 (17.8)
13.165
<0.001
CD (n = 48)
None
Mild
Moderate/severe
F-value
P-value
RFIPC dimensions
F1 Impact of disease
28.5 (25.1)
31.7 (19.0)
44.6 (19.1)
2.633
NS
F2 Expectancy
38.8 (36.4)
41.4 (26.7)
44.2 (29.1)
.102
NS
F3 Treatment
34.3 (33.3)
28.9 (18.6)
30.7 (22.4)
.176
NS
F4 Intimacy
19.1 (28.1)
20.6 (19.9)
27.2 (26.7)
.489
NS
F5 Stigma
16.8 (29.4)
26.4 (23.6)
21.2 (19.2)
.597
NS
F6 Complications
28.0 (28.7)
30.8 (20.8)
23.1 (20.7)
.572
NS
Sum score
28.6 (26.3)
31.4 (16.6)
35.1 (18.8)
.377
NS
Abbreviations: RFIPC: rating form of inflammatory bowel disease patient concerns, F1 : F6 (Factors 1–6), UC: ulcerative colitis, CD: Crohn’s disease. Figures are presented as means and standard deviations.
